Physician profile
Sonia Sandhu
NPI 1538492723
$6,870.42
in general payments reported to CMS, 2019-2025
47 companies · $3,840 in 2025
The $3,840 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.71 · 2021: $119 · 2022: $973 · 2023: $882 · 2024: $1,039 · 2025: $3,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,110 · Consulting Fee: $2,560 · Travel and Lodging: $47.18 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,110.45 |
| Consulting Fee | $2,560.00 |
| Travel and Lodging | $47.18 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $2,750.54 | 2025 | Imetelstat |
| Pfizer INC. | $373.02 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $349.72 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $296.03 | 2022-2025 | |
| Abbvie INC. | $287.39 | 2021-2025 | |
| Seagen INC. | $239.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $203.91 | 2022-2025 | Enhertu, Imfinzi |
| Glaxosmithkline, LLC. | $169.09 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $133.47 | 2022-2024 | |
| Penumbra, INC. | $131.66 | 2022 | |
| Gilead Sciences, INC. | $126.02 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $115.25 | 2022-2025 | Opdivo, Opdualag |
| Genmab U.S., INC. | $104.64 | 2024 | Epkinly, Tivdak |
| Eisai INC. | $103.83 | 2022-2024 | |
| Array Biopharma INC | $97.69 | 2025 | Mektovi, Braftovi, Tukysa |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $92.32 | 2019-2024 | Jakafi |
| Genentech USA, INC. | $86.56 | 2023-2025 | Alecensa, Tecentriq, Gavreto |
| Daiichi Sankyo INC. | $85.80 | 2022-2025 | Enhertu |
| Karyopharm Therapeutics INC. | $83.47 | 2022-2024 | Xpovio |
| Puma Biotechnology, INC. | $82.00 | 2023-2025 | Nerlynx |
| Janssen Biotech, INC. | $77.93 | 2023-2025 | Tecvayli, Talvey, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $68.81 | 2022-2024 | Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $68.11 | 2023-2025 | |
| Amgen INC. | $59.02 | 2022 | |
| Celgene Corporation | $55.74 | 2023-2025 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $49.86 | 2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $48.56 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Cti Biopharma Corp. | $46.59 | 2023 | Vonjo |
| Astellas Pharma US INC | $45.33 | 2024-2025 | Xospata, Padcev |
| Sobi, INC | $42.88 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $41.75 | 2023-2024 | |
| Blueprint Medicines Corporation | $36.06 | 2022-2023 | Ayvakit |
| Jazz Pharmaceuticals INC. | $35.96 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $30.68 | 2025 | Orgovyx |
| Stemline Therapeutics INC. | $26.38 | 2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $25.25 | 2024 | Clonoseq |
| Lilly USA, LLC | $25.07 | 2023 | Verzenio |
| Foundation Medicine, INC. | $24.08 | 2022 | |
| Tolmar, INC. | $22.35 | 2023 | |
| Boston Scientific Corporation | $21.59 | 2024 | |
| Deciphera Pharmaceuticals INC. | $21.43 | 2024 | Qinlock |
| Alexion Pharmaceuticals, INC. | $19.74 | 2023 | Ultomiris |
| Emd Serono, INC. | $19.41 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.09 | 2024 | Onivyde |
| Mirati Therapeutics, INC. | $16.77 | 2023 | Krazati |
| Morphosys, US INC. | $12.28 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.